Mirum Pharmaceuticals (MIRM) Net Cash Flow Growth (1y) (2020 - 2026)
Mirum Pharmaceuticals (MIRM) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 53.46% |
| 10 | Mirum Pharmaceuticals | 6.78 Bn | 6.39 Bn | 131.08 Mn | 353.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353.47% |
| Dec 31, 2025 | 1,660.35% |
| Sep 30, 2025 | 625.57% |
| Jun 30, 2025 | 120.41% |
| Mar 31, 2025 | -171.54% |
| Dec 31, 2024 | 105.42% |
| Sep 30, 2024 | -265.78% |
| Jun 30, 2024 | -146.80% |
| Mar 31, 2024 | -22.72% |
| Dec 31, 2023 | -114.78% |
| Sep 30, 2023 | 131.54% |
| Jun 30, 2023 | 1,535.41% |
| Mar 31, 2023 | 42.14% |
| Dec 31, 2022 | -110.39% |
| Sep 30, 2022 | 46.01% |
| Jun 30, 2022 | 619.00% |
| Mar 31, 2022 | 129.06% |
| Dec 31, 2021 | -19.07% |
| Sep 30, 2021 | -5.33% |
| Jun 30, 2021 | -88.57% |